Immix intends to use the net proceeds from this offering, together with its existing cash and cash equivalents to fund NXC-201 development and for working capital and general corporate purposes. Immix ...
Tazemetostat is a first-in-class methyltransferase inhibitor of EZH2 developed by Epizyme, an Ipsen company. HUTCHMED entered into a strategic collaboration with Epizyme to research, develop, ...
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today ...
Updated clinical data presented at ASH show robust efficacy, rapid onset of remission, high incidence of MRD 1 -negativity, and an encouraging survival signal with ICT01 in combination with ...
Lyell management will host an investor webcast with presenting author and ronde-cel investigator Sarah M. Larson, MD, Associate Professor at the David Geffen School of Medicine, University of ...
A webcast of the conference call can be accessed by visiting “Investor Events” on the investor relations section of the Wave Life Sciences website: ...
The publication, titled “Prime Editing for p47-phox Chronic Granulomatous Disease,” reports initial data for two patients treated in the Phase 1/2 trial of PM359, which was designed to assess safety, ...
Findings further strengthen rationale for ongoing global Phase 3 TERZO study in nodal TFH lymphoma. BERKELY HEIGHTS, N. J., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. ( ), an integrated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback